Table 2 Patients characteristics
Characteristics | 1.5-T MRI cohort (n = 85) | 3.0-T MRI cohort (n = 49) | P |
|---|---|---|---|
PD-L1status (No. %) | 0.756 | ||
High expression | 44 (51.76%) | 24 (48.98%) | |
Low expression | 41 (48.24%) | 25 (51.02%) | |
PD-L1 CPS (mean ± SD) | 30.75 ± 26.28 | 37.65 ± 31.57 | 0.177 |
Age (mean ± SD) | 50.53 ± 10.39 | 50.43 ± 13.36 | 0.961 |
Gender (No. %) | 0.978 | ||
Male | 64 (75.29%) | 37 (75.51%) | |
Female | 21 (24.71%) | 12 (24.49%) | |
Histology, WHO type | 0.729 | ||
II | 46 (54.12%) | 25 (51.02%) | |
III | 39 (45.88%) | 24 (48.98%) | |
T stage (No. %) | 0.948 | ||
T1 | 7 (8.23%) | 4 (8.16%) | |
T2 | 21 (24.71%) | 12 (24.49%) | |
T3 | 38 (44.71%) | 24 (48.98%) | |
T4 | 19 (22.35%) | 9 (18.37%) | |
N stage (No. %) | 0.79 | ||
N0 | 3 (3.53%) | 2 (4.08%) | |
N1 | 20 (23.53%) | 14 (28.57%) | |
N2 | 37 (43.53%) | 17 (34.69%) | |
N3 | 25 (29.41%) | 16 (32.66%) | |
M stage | 0.783 | ||
M0 | 75 (88.24%) | 44 (89.80%) | |
M1 | 10 (11.76%) | 5 (10.20%) | |
Clinical stage | 0.629 | ||
II | 13 (15.29%) | 4 (8.16%) | |
III | 32 (37.65%) | 22 (44.90%) | |
IVa | 30 (35.30%) | 18 (36.73%) | |
IVb | 10 (11.76%) | 5 (10.21%) |